Published in Emerg Microbes Infect on January 06, 2016
Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses. Int J Mol Sci (2016) 1.39
Elevated Concentration of Defensins in Hepatitis C Virus-Infected Patients. J Immunol Res (2016) 0.75
A DNA aptamer efficiently inhibits the infectivity of Bovine herpesvirus 1 by blocking viral entry. Sci Rep (2017) 0.75
Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infection. J Int Med Res (2016) 0.75
Design of Multivalent Inhibitors for Preventing Cellular Uptake. Sci Rep (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
The global burden of hepatitis C. Liver Int (2009) 8.89
Viral membrane fusion. Nat Struct Mol Biol (2008) 8.54
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol (1998) 7.78
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 6.19
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol (2005) 3.35
Tetraspanins. Cell Mol Life Sci (2001) 3.33
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 3.10
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med (2015) 2.92
Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol (2001) 2.90
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol (1990) 2.60
Tea polyphenols for health promotion. Life Sci (2007) 2.50
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology (2007) 1.85
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol (2007) 1.73
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol (2015) 1.67
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem (2004) 1.55
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A (2013) 1.43
Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol (2010) 1.42
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology (2012) 1.34
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem (2004) 1.32
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem (2006) 1.32
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol (2011) 1.28
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology (2012) 1.26
New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology (2013) 1.26
Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci U S A (2010) 1.25
Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta (2011) 1.21
hepatitis c Virus p7 is critical for capsid assembly and envelopment. PLoS Pathog (2013) 1.20
Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem (2008) 1.18
Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med (2006) 1.18
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis (2012) 1.13
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol (2012) 1.12
Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol (2009) 1.11
In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res (2011) 1.08
Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology (2003) 1.08
A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology (2012) 1.06
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
The structure and function of Niemann-Pick C1-like 1 protein. Curr Opin Lipidol (2008) 1.04
New targets for antiviral therapy of chronic hepatitis C. Liver Int (2012) 1.00
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol (2012) 0.99
Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology (2014) 0.99
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology (2015) 0.98
A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology (2012) 0.94
The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership. Biochem J (2009) 0.94
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology (2006) 0.94
Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses (2010) 0.93
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother (2015) 0.92
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs (2015) 0.91
Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res (2013) 0.91
Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol (2013) 0.90
Human serum amyloid A protein inhibits hepatitis C virus entry into cells. J Virol (2007) 0.90
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90
Differential expression of claudin 1, 3, and 4 during normal mammary gland development in the mouse. DNA Cell Biol (2006) 0.90
Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs (2015) 0.90
Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol (2011) 0.89